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Other “true” MCSCs may remain 
quiescent, and thus the MCSC reservoir 
is preserved during phototherapy.
If bona fide MCSCs are activated by 
phototherapy, what is the underlying 
mechanism responsible for this effect 
of uncoupling MCSC activation from 
hair follicle stem cell activation? Does it 
work directly through activating MCSCs 
or indirectly through modifying the 
environment? How do we activate and 
enhance this effect in patients who do 
not respond to phototherapy? To answer 
these questions, we need new method-
ologies (Figure 1c). The method to isolate 
and culture murine MCSCs developed 
by Nishikawa’s group brings us closer 
to a position in which we are capable of 
isolating and culturing human MCSCs 
for treatment, pharmaceutical testing, 
and pathophysiological investigation.
In summary, the breakthrough in cul-
turing technology for murine MCSCs will 
allow further bench biomolecular pertur-
bation and characterization. The in vitro 
studies will be complementary to results 
obtained in vivo. Furthermore, the con-
cept and approach Nishikawa-Torikai 
et al. (2011) propose can be developed 
and applied to isolating human MCSCs. 
Their findings are expected to facilitate 
research in human melanocytes as well 
as clinical applications of MCSCs.
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Axl of evil?
Andrew E. Aplin1,2
Receptor tyrosine kinases (RTKs) play key roles in the initiation and progres-
sion of human skin cancers, yet the importance of some RTKs remains poorly 
understood. In this issue, Sensi et al. provide new insights into the expres-
sion and function of the RTK, Axl, in melanoma. The investigators show that 
Axl is frequently expressed in melanoma cell lines, particularly mutant NRAS-
harboring lines, and that Axl activation by its ligand, Gas6, probably occurs via 
both autocrine and paracrine mechanisms. Gene signatures from Axl-expressing 
cell lines are similar to published signatures from poorly differentiated tumors 
displaying high metastatic potential. functionally, Axl was required for the inva-
sive and migratory properties of Axl-expressing melanoma cell lines. These data 
emphasize that targeting the Gas6–Axl signaling axis should be investigated as a 
strategy to inhibit prometastatic properties in poorly differentiated melanomas.
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Axl was originally identified as a 
transforming gene in chronic myelog-
enous leukemia (Liu et al., 1988). Its 
name was derived from the Greek 
word anexelekto, meaning “uncon-
trolled” (O’Bryan et al., 1991), and 
it was characterized as a receptor 
tyrosine kinase (RTK) in the TAM 
(Tyro-3, Axl, Mer) subfamily. Aberrant 
expression and activation of RTKs are 
implicated in melanoma progression 
(Tworkoski et al., 2011), as well as in 
melanoma resistance to targeted ther-
apies (Villanueva et al., 2010). Axl has 
been found to be upregulated in many 
cancer types; however, the impor-
tance of this RTK in melanoma has 
not been clearly elucidated. In their 
article in this issue, Sensi et al. seek to 
fill this gap.
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Sensi and co-workers detected high 
Axl expression in 22 of 58 of cell lines 
(38%) in a melanoma progression 
panel. The frequency of Axl expression 
increased with disease progression, with 
30% of primary tumor lines and 40% of 
metastases displaying expression. Other 
TAM subfamily RTKs, Tyro3 and Mer, 
were expressed in a low percentage of 
melanomas, and these lines lacked Axl 
expression. NRAS mutations are found 
in 15–20% of melanomas and are mutu-
ally exclusive from the approximately 
50% of melanomas that harbor BRAF 
mutations. A high proportion of melano-
ma lines that highly expressed Axl were 
of a mutant NRAS genotype with an 
underrepresentation of mutant BRAF and 
wild-type BRAF/NRAS genotypes.
a role for axl in melanoma migration  
and invasion
Gene signatures have been utilized to 
stratify melanomas into distinct sub-
sets. An interesting aspect of the study 
by Sensi et al. (2011) is their analysis of 
published gene sets to identify signa-
tures that positively or negatively cor-
relate with Axl expression. Of the genes 
positively correlated with Axl, there was 
high representation by genes associated 
with extracellular matrix interactions and 
remodeling, indicating a possible role 
for Axl in invasion. Furthermore, inhibit-
ing Axl function in a high Axl-expressing 
melanoma cell line with short interfer-
ing RNAs or a pharmacological inhibitor 
led to reduced invasion and migration. 
Comparable observations were reported 
recently by an independent group 
(Tworkoski et al., 2011). However, 
whereas Sensi and colleagues show that 
Axl depletion did not dramatically affect 
proliferation, Tworkoski et al. indicate that 
knockdown of Axl inhibited proliferation 
in some lines. Nevertheless, the consen-
sus is that Axl mediates proinvasive and 
metastatic behavior in melanoma cells.
Axl expression was also associ-
ated with poorly differentiated tumors. 
Additional biochemical and immunohis-
tochemical analyses of tumors revealed 
a negative correlation between Axl and 
expression of microphthalmia-associated 
transcription factor (MITF). These data 
are consistent with a model of mela-
noma plasticity in which melanomas 
switch between proliferative and inva-
sive states based on cues from the tumor 
microenvironment (Hoek et al., 2008). 
These distinct states can be distinguished 
by analysis of gene expression profiles. 
MITF, a transcription factor well known 
to regulate melanocyte differentiation 
and survival (Widlund and Fisher, 2003), 
represents a marker for proliferative, non-
invasive cells, and Axl is one of the genes 
associated with the invasive phenotype 
(Hoek et al., 2008). Whereas most of 
the tumors studied by Sensi et al. (2011) 
show high Axl and very low MITF stain-
ing, or vice versa, two tumors did show 
expression of both antigens. It would 
therefore be interesting to study other 
melanoma collections for heteroge-
neous, but inversely correlated, expres-
sion of Axl and MITF within the same 
tumor and to determine whether Axl is 
preferentially upregulated at a tumor’s 
leading edge. A potential positive corre-
lation between Brn2 and Axl should also 
be explored because Brn2 downregu-
lates MITF and promotes invasive prop-
erties (Goodall et al., 2008). However, it 
should be noted that decreased invasion 
and migration of Axl knockdown cells 
were independent of changes in MITF 
expression and that other factors, such 
as TCF4, have been implicated as a hub 
controlling invasive properties.
targeting axl signaling
As noted above, Sensi and colleagues’ 
study utilizes a pharmacological inhibi-
tor of Axl, R428, which was originally 
developed by Rigel. R428 inhibits Axl at 
low nanomolar concentrations with less 
potent activity toward Tie-2, Ftl-1, Flt-3, 
Ret, and Abl, and it is highly selective 
toward Axl compared with Tyro-3 and 
Mer (Holland et al., 2010). Based on the 
preclinical data presented by Sensi et al., 
Axl inhibitors are unlikely to produce 
strong tumor shrinkage as a monothera-
peutic approach in melanomas. Rather, 
they may block the rapid dissemination 
that frequently occurs in melanoma and/
or in combination with inhibitors that 
arrest proliferation and thus promote the 
switch to a highly invasive state. Notably, 
studies from the Hoek lab have shown 
that inhibition of RAF–MEK signaling 
induces an invasive-like morphology 
in melanoma cells cultured on a base-
ment membrane-like matrix; however, 
whether Axl expression is modulated 
by ERK1/2 pathway inhibitors remains 
unclear. Another target is Gas6, the 
ligand for Axl. Gas6 is produced in a 
biologically active form in over half of 
the Axl-expressing melanomas and likely 
activates Axl signaling via both autocrine 
and paracrine mechanisms.
Although Axl expression was detected 
with a significantly higher frequency in 
mutant NRAS melanomas, it may also 
be relevant to mutant BRAF cells. The 
RAF inhibitor, PLX4032 (vemurafenib), 
has been approved by the US Food and 
Drug Administration, but its clinical 
benefit is often short-lived in patients 
with mutant BRAF V600 because of 
acquired resistance. RTKs are frequent-
ly upregulated in melanoma cells that 
have acquired resistance to RAF inhibi-
tors (Villanueva et al., 2010). Notably, 
Axl was a “hit” from a screen to identify 
kinases that, when overexpressed, pro-
mote resistance to PLX4720, the tool 
compound for PLX4032 (Johannessen 
et al., 2010). Sensi et al. show that Gas6 
signaling via Axl promotes Akt signaling. 
Activation of Akt, albeit downstream of 
insulin-like growth factor 1 receptor, 
has previously been implicated as one 
mechanism of acquired resistance to 
RAF inhibitors (Villanueva et al., 2010). 
The prevailing consensus is that multiple 
mechanisms will underlie resistance 
Clinical Implications
•  Axl expression may serve as a biomarker for poorly differentiated tumors 
with high metastatic potential.
•  Axl is druggable. Small-molecule inhibitors to Axl may be an important 
component of combinatorial strategies to target a subset of melanomas 
that are poorly differentiated, as indicated by low MITF expression.
•  Upregulation of Axl and/or Axl-mediated signaling may contribute 
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to RAF inhibitors; thus, it will be 
worthwhile to examine changes in Axl 
expression in cell line–based models 
of resistance to RAF inhibitors, as well 
as in samples from relapsed patients. In 
summary, Gas6–Axl signaling may be 
a signaling “axis of evil” in melanoma, 
and it should be investigated further as a 
“druggable” pathway.
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Infantile Hemangioma Research: 
Looking Backward and forward
Ilona J. Frieden1
This is a remarkable time to be a student of infantile hemangiomas (IHs). IH is a 
common tumor, estimated to occur in approximately 4% of infants. Studied for 
many decades, the acquisition of knowledge and pace of IH research are accel-
erating. The article by Greenberger et al. in this issue is a welcome addition to 
the literature. It examines rapamycin as a possible treatment for IH that could 
potentially be curative because suppression of self-renewal of stem cells might 
deplete hemangiomas of the stem cells from which they originate. However, 
before we get too enthusiastic about using rapamycin for IHs, it is important to 
reflect on lessons learned from previous hemangioma therapies.
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Infantile hemangioma research  
in the 20th century
Although there was evidence as 
far back as the late 1930s that 
infantile hemangioma (IH) involuted 
spontaneously, studies describing the 
natural history of IHs published in the 
1960s more clearly delineated the 
characteristic natural history of rapid 
growth followed by gradual involu-
tion. X-irradiation therapy, an effective 
treatment for hemangiomas, was used 
widely from 1930 to 1950 (Mulliken 
and Young, 1988). Starting in the 1950s, 
prominent physicians—among them 
the founders of the subspecialty of pedi-
atric dermatology, Alvin Jacobs and 
Sidney Hurwitz—decried the use of 
X-irradiation and attempts at preemptive 
surgical removal, advocating a hands-
off approach. Why, after all, would you 
treat something that would go away on 
its own? This was sage advice, but it had 
its limitations. Although most heman-
giomas involute without leaving major 
sequelae, a significant minority are 
problematic.
An important therapeutic break-
through came in the mid-1960s, when 
systemic corticosteroids were found 
to be an effective treatment. Despite 
their many potential side effects, 
prednisolone and other corticosteroids 
became a mainstay of treatment for 
those hemangiomas severe enough to 
require systemic therapy. Treatment of 
IH causing medical morbidities (e.g., 
amblyopia or airway disease) was 
clearly necessary. Less clear, however, 
was the approach for hemangiomas 
that are not medically endangering but 
are arguably life-altering—leaving scar-
ring or permanent distortion of impor-
tant anatomic structures of the face, 
such as the nose and lips.
In 1982, Mulliken and Glowacki 
proposed a biologic classification of 
vascular birthmarks into “hemangio-
mas” and “vascular malformations.” 
This was a major conceptual break-
through that helped to clearly delin-
eate IHs as an entity distinct from 
other vascular birthmarks (particularly 
venous malformation, with which it 
was often lumped, under the diag-
nosis of “cavernous hemangioma”) 
(Mulliken and Glowacki, 1982). Like 
many other important ideas, this one 
seems obvious in retrospect. At the 
time, however, nosologic confusion 
was a major obstacle to understand-
ing the biology of IH; this confusion 
hampered efforts to define optimal 
treatments. A chronic lack of fund-
ing also hindered research. Without 
funding from the National Institutes 
